During the last session, Health Catalyst Inc (NASDAQ:HCAT)’s traded shares were 1.5 million, with the beta value of the company hitting 1.48. At the end of the trading day, the stock’s price was $4.43, reflecting an intraday loss of -2.64% or -$0.12. The 52-week high for the HCAT share is $9.24, that puts it down -108.58 from that peak though still a striking 15.12% gain since the share price plummeted to a 52-week low of $3.76. The company’s market capitalization is $311.03M, and the average trade volume was 773.23K shares over the past three months.
Health Catalyst Inc (HCAT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.57. HCAT has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.0.
Health Catalyst Inc (NASDAQ:HCAT) trade information
Health Catalyst Inc (HCAT) registered a -2.64% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.64% in intraday trading to $4.43, hitting a weekly high. The stock’s 5-day price performance is 0.91%, and it has moved by -21.17% in 30 days. Based on these gigs, the overall price performance for the year is -46.30%.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 36.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, HCAT is trading at a discount of -58.01% off the target high and -58.01% off the low.
Health Catalyst Inc (HCAT) estimates and forecasts
In the rating firms’ projections, revenue will increase 9.15% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 79.14M as predicted by 13 analyst(s). Meanwhile, a consensus of 13 analyst(s) estimates revenue growth to 82.87M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 74.72M and 75.9M respectively. In this case, analysts expect current quarter sales to grow by 5.92% and then jump by 9.19% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.24%. While earnings are projected to return 5.25% in 2025, the next five years will return 39.50% per annum.
HCAT Dividends
Health Catalyst Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 4.53 million shares, is of VANGUARD GROUP INC’s that is approximately 7.7263% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $28.93 million.
